What are the available payment terms for this product?

We accept LC, T/T, D/P, PayPal, Western Union, Small-amount payment, and Money Gram.

What is the typical lead time for orders?

The average lead time is 1-3 months, applicable for both peak season and off-season periods.

Which markets do you primarily export to?

Our main markets include Eastern Europe, Southeast Asia, and the Middle East.

Compound Amino Acid (9AA) Intravenous Solution Glass Bottle IV 13.98g/250ml

Name: Compound Amino Acid (9AA) Intravenous Solution Glass Bottle IV 13.98g/250ml
Brand: Beijing DC-Pharma Co., Ltd.
SKU: 2018560432

Beijing, ChinaBeijing DC-Pharma Co., Ltd.

US$1.20-1.50

20,000 Bottle

Product profile

Application

Internal Medicine

Usage Mode

Suitable for

Elderly, Children, Adult

Model NO.

13.98g/250ml

State

Liquid

Shape

Injection

Type

Organic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Drug Reg./Approval No.

Guoyaozhunzi

Ingredient

Amino Acids

Standard

Packaging

Box

Market

Foreign

Transport Package

Glass Bottles in Carton

Specification

250ml: 13.98g

Origin

P. R. China

HS Code

3004909099

Production Capacity

10 Million Bottles/Year

Key features

Essential Nutritional Support: Provides nitrogen for patients unable to tolerate oral nutrition, supporting total parenteral nutrition (TPN).

Suitable for All Ages: Indicated for elderly, children, and adults, with dosage adjusted for infants and adults based on weight.

Fluid Restricted Patient Care: Concentrated amino acid source designed for patients with fluid restrictions, such as those with renal failure.

Flexible Dosing Protocol: Daily dose ranges from 0.75 to 1.68 g/kg depending on metabolic needs, trauma severity, and clinical response.

Comprehensive Electrolyte Management: Supports maintenance of serum potassium levels (60-180 mEq/day) and requires careful monitoring of electrolytes.

Prevention of Fatty Acid Deficiency: Recommended to co-administer fat emulsion for parenteral nutrition lasting more than 5 days to prevent EFAD.

Global Market Availability: Exported to Eastern Europe, Southeast Asia, and the Middle East with flexible payment terms including LC and T/T.

High Quality Packaging: Supplied in glass bottles with box packaging, ensuring product integrity for international pharmaceutical standards.

Company profile

Years of Export ExperienceHigh Repeat Buyers ChoiceImporters and ExportersMulti-language Pioneer

Beijing DC-Pharma Co., Ltd.

Beijing, China

Business Type: Manufacturer/Factory, Trading CompanyExport Year: 2022-03-25Average Response Time: >24hTerms of Payment: LC, T/T, D/P, etc.International Commercial Terms(Incoterms): FOB

About Our Factory & Business Background

AddressRoom No. 217, Second Floor, Wangjing Street, Chaoyang Dist, Beijing, china

Average Lead TimePeak Season Lead Time: 1-3 months Off Season Lead Time: 1-3 months

Our Production Capability & Technical Expertise

Main ProductsInjections, Ampoules, Tablets, Capsules, Powder

Our Industry Experience & Global Business Record

Main MarketsEastern Europe, Southeast Asia, Mid East

Product Q&A

Q:What is the primary indication for Compound Amino Acid IV?

It is indicated as a source of nitrogen for nutritional support in patients who cannot tolerate, or have inadequate, oral nutrition.

Q:How is the dosage determined for different patients?

Dosage depends on metabolic requirements and clinical response. It ranges from 0.75 g/kg for adults to 1.68 g/kg for infants, adjusted for trauma or malnutrition.

Q:Is this product suitable for patients with fluid restrictions?

Yes, it provides a concentrated source of amino acids specifically to meet protein requirements for patients who are fluid restricted, such as those with renal failure.

Q:What monitoring is required during treatment?

Frequent monitoring of nitrogen balance, body weight, blood osmolarity, serum electrolytes (especially potassium), and serum lipids is mandatory.

Q:When should fat emulsion be co-administered?

Fat emulsion should be considered when prolonged parenteral nutrition (more than 5 days) is required to prevent essential fatty acid deficiency (EFAD).